Overview
Micropep develops AI-powered discovery and development platforms for bioactive micropeptides used in sustainable crop protection and stimulation. The company combines generative AI, predictive modeling, and experimental data to accelerate the identification and optimization of micropeptide-based biocontrol products targeting fungal diseases, bioherbicide applications, and crop health enhancement. Micropep's lead product MPD-01, an antimicrobial peptide targeting Asian soybean rust, mildews, and late blight, is currently undergoing field trials across Europe, the US, and Latin America in preparation for regulatory submission.
Frequently asked questions
- What is Micropep's core technology platform?
- Micropep's Krisalix platform is an AI-powered discovery system that combines generative AI, predictive modeling, and high-quality experimental data across biology, chemistry, and agronomy to accelerate the discovery and development of bioactive micropeptides. The platform dramatically reduces R&D timelines and costs compared to traditional peptide development approaches.
- What are micropeptides and how do they work?
- Micropeptides (miPEPs) are short chains of naturally occurring amino acids that regulate cellular physiology without modifying plant DNA. Micropep's technology fine-tunes plants' natural capabilities by controlling gene silencing effects, allowing crops to overcome disease and stress more effectively while maintaining environmental safety.
- What products has Micropep developed and what is their regulatory status?
- Micropep's lead product MPD-01 is a broad-spectrum antimicrobial peptide (AMP) biofungicide targeting Asian soybean rust, phytophthora infections in potatoes, and mildews in grapes. MPD-01 is currently undergoing field trials across Europe, the US, and Latin America and is being prepared for regulatory submission. The company's pipeline includes additional candidates for bioherbicide and biofungicide applications.
- In which geographies is Micropep conducting development and trials?
- Micropep is conducting field trials for MPD-01 across Europe, the US, and Latin America. The company operates as a global leader in micropeptide technology with an international development footprint.
- What manufacturing capabilities does Micropep have?
- Micropep has achieved key biomanufacturing milestones including batch regulatory production at 15m³ scale and scale-up capabilities at 75m³, demonstrating readiness for commercial production of micropeptide-based products.